CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 13, 2012--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi
therapeutics company, today announced that it has commenced an
underwritten public offering of 7,000,000 shares of its common stock.
All of these shares are being sold by Alnylam.
J.P. Morgan Securities LLC is acting as sole book-running manager for
the proposed offering. Alnylam intends to grant the underwriter a 30-day
option to purchase up to an additional 1,050,000 shares to cover
overallotments, if any. The offering is subject to market conditions,
and there can be no assurance as to whether or when the offering may be
completed, or as to the final size or terms of the offering.
The securities described above are being offered by Alnylam pursuant to
a registration statement previously filed and declared effective by the
Securities and Exchange Commission. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy any
securities nor shall there be any sale of these securities in any state
in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such state.
The offering of these securities will be made only by means of a
prospectus and the related prospectus supplement. Before you invest, you
should read the prospectus and the related prospectus supplement and any
other document Alnylam has filed with the SEC for more complete
information about Alnylam and this offering. You may get these documents
for free by visiting EDGAR on the SEC Website at www.sec.gov.
Alternatively, copies of the prospectus and the related prospectus
supplement can be obtained by contacting J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New
York 11717 (telephone number: 866-803-9204).
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics
based on RNA interference, or RNAi. The company is leading the
translation of RNAi as a new class of innovative medicines with a core
focus on RNAi therapeutics for the treatment of genetically defined
diseases, including ALN-TTR for the treatment of transthyretin-mediated
amyloidosis (ATTR), ALN-PCS for the treatment of severe
hypercholesterolemia, ALN-HPN for the treatment of refractory anemia,
ALN-APC for the treatment of hemophilia, and ALN-TMP for the treatment
of hemoglobinopathies. As part of its “Alnylam 5x15TM”
strategy, the company expects to have five RNAi therapeutic products for
genetically defined diseases in clinical development, including programs
in advanced stages, on its own or with a partner by the end of 2015.
Alnylam has additional partner-based programs in clinical or development
stages, including ALN-RSV01 for the treatment of respiratory syncytial
virus (RSV) infection, ALN-VSP for the treatment of liver cancers, and
ALN-HTT for the treatment of Huntington’s disease. The company’s
leadership position on RNAi therapeutics and intellectual property have
enabled it to form major alliances with leading companies including
Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko
Kirin, and Cubist. In addition, Alnylam and Isis co-founded Regulus
Therapeutics Inc., a company focused on discovery, development, and
commercialization of microRNA therapeutics; Regulus has formed
partnerships with GlaxoSmithKline and Sanofi. Alnylam has also formed
Alnylam Biotherapeutics, a division of the company focused on the
development of RNAi technologies for applications in biologics
manufacturing, including recombinant proteins and monoclonal antibodies.
Alnylam’s VaxiRNA™ platform applies RNAi technology to improve the
manufacturing processes for vaccines; GlaxoSmithKline is a collaborator
in this effort. Alnylam scientists and collaborators have published
their research on RNAi therapeutics in over 100 peer-reviewed papers,
including many in the world’s top scientific journals such as Nature,
Nature Medicine, Nature Biotechnology, and Cell.
Founded in 2002, Alnylam maintains headquarters in Cambridge,
Alnylam Forward-Looking Statements
Statements in this release concerning Alnylam’s future expectations,
plans and prospects, including Alnylam's intention to publicly offer
shares of its common stock, constitute forward-looking statements for
the purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by these forward-looking statements as a result of
various important factors, including risks related to fluctuations in
our stock price, those associated with market conditions and the
satisfaction of customary closing conditions related to the proposed
offering, as well as those risks more fully discussed in the “Risk
Factors” section of Alnylam’s most recent Annual Report on Form 10-K on
file with the Securities and Exchange Commission. In addition, any
forward-looking statements represent Alnylam’s views only as of today
and should not be relied upon as representing Alnylam’s views as of any
subsequent date. Alnylam disclaims any obligation to update any
Source: Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Cynthia Clayton, 617-551-8207
President, Investor Relations and
Vice President, Finance and Treasurer